Of the two patients who had regular follow-up, BM biopsies after stopping romiplostim partial resolution of reticulin was seen in one [ ].
IL is a thrombopoietic growth factor that induces proliferation of megakaryocyte progenitors and megakaryocyte maturation [ ]. There is one report of the use of recombinant human IL in the treatment of severe thrombocytopenia complicating SLE [ ]. The use of immune complexes i. Intravenous anti-D could also be considered instead of IVIG to treat thrombocytopenia in patients who have not had splenectomy [ ].
Peripheral blood cytopenias are common in SLE and their management can be challenging. In many individual cases, they are mild and do not require specific therapy. However, cytopenia may be a marker for active disease in other organ systems and, when severe, may be associated with increased mortality.
A number of novel therapeutic approaches to the management of cytopenias, including thrombopoeitin receptor agonists and anti-B-cell therapies, in particular, are showing great promise. Disclosure statement : The authors have declared no conflicts of interest. Google Scholar. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. An approach to the investigation of cytopenias in SLE.
Treatment of cytopenias in SLE. Newer therapies for cytopenias complicating SLE. The management of peripheral blood cytopenias in systemic lupus erythematosus. Hepburn , Alastair L. Oxford Academic. Santosh Narat.
Justin C. Revision received:. Cite Cite Alastair L. Select Format Select format. Permissions Icon Permissions. Abstract Haematological complications are frequently seen in SLE. T able 1 Causes of cytopenia in SLE. Open in new tab. Open in new tab Download slide. Flow chart for the management of thrombocytopenia in SLE. Tan ACR classification. The revised criteria for the classification of systemic lupus erythematosus.
Google Scholar Crossref. Search ADS. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of SLE patients during long-term follow-up.
Google Scholar PubMed. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus.
Study of lymphocyte subpopulations in normal humans and patients with systemic lupus erythematosus by fractionation of peripheral blood lymphocytes on a discontinuous Ficoll gradient. Relationship of the clinical course of systemic lupus erythematosus to the presence of circulating lymphocytotoxic antibodies.
Association of cold-reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Diminished expression of complement regulatory proteins CD55 and CD59 in lymphocytes from systemic lupus eyrthematosus patients with lymphopenia. The role of complement regulatory proteins CD55 and CD59 in the pathogenesis on autoimmune hemocytopenias.
Increased expression of decay-accelerating factor but not CD59 on peripheral blood leucocytes in patients with systemic lupus erythematosus and rheumatoid arthritis.
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Anti-granulocyte opsonic activity in sera from patients with systemic lupus erythematosus.
TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Neutropenia associated with myelofibrosis in systemic lupus erythematosus. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. Moderate and severe neutropenia in patients with systemic lupus erythematosus. Systemic lupus erythematosus in Malaysia: a study of patients and comparison of prevalence and disease expression in different racial and gender groups.
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1, patients. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population.
Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia.
Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus. Autoantibody to c-Mpl thrombopoietin receptor in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.
Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems.
Lupus thrombocytopenia: clinical implications and prognostic significance. Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus.
Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Human parvovirus B19 infection during the inactive stage of systemic lupus erythematosus. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus.
Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study.
Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus. Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus.
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus.
Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. A study of 20 SLE patients with intravenous immunoglobulin—clinical and serologic response. High-dose intravenous immunoglobulin for lupus nephritis — a salvage immunomodulation. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus.
Danazol for thrombocytopenia in pregnancy with underlying systemic lupus erythematosus. A case of systemic lupus erythematosus expressing intractable thrombocytopenia remedied effectively by intermittent and continuous administrations of a small amount of immunoglobulin.
Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases.
Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports.
Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus. A case report of the efficacy of apheresis for refractory autoimmune thrombocytopenia in a patient with systemic lupus erythematosus associated hemolytic anemia. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus. Recovery after exchange plasmapheresis. Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia.
Inhibition of hematopoiesis by a plasma factor in a case of aplastic anemia associated with systemic lupus erythematosus. Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.
Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil.
Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Researchers in Thailand conducted a prospective cohort study of 89 patients newly diagnosed with systemic lupus erythematosus SLE; mean age, Patients who had been observed for at least 1 year or who died during the study period were included.
Leukopenia was present at diagnosis in Leukopenia, lymphopenia and neutropenia had cumulative prevalence of One patient had persistent leukopenia but had not received any immunosuppressive agent. Twenty-seven patients Although [white blood cells] have a major role to prevent infection, our study could not demonstrate the association of leukopenia and severe infection. Healio News Rheumatology Lupus. Usually, your doctor will request that your white blood cell differential is also assessed as a part of your CBC.
There are five types of white blood cells: neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Each group of white blood cells plays a different role in the immune response. The white blood cell differential will measure whether these cells are present in your body in normal proportions, revealing information about certain deficiencies in your immune system.
A complete blood count will also assess whether red blood cell counts are low. All information contained within the Johns Hopkins Lupus Center website is intended for educational purposes only.
0コメント